01600nas a2200313   4500000000100000008004100001260003600042653001000078653000900088653002000097653001100117653002300128653002400151653000900175653001500184653000900199653002900208100001800237700001300255700002300268700001400291700001800305245007200323856010600395300001000501490000700511520075400518022001401272       2011                            d  c2011 Nov-DecbScieloaSao Paulo10aAdult10aAged10aEarly Diagnosis10aHumans10aLeprostatic Agents10aLeprosy, Borderline10aMale10aRecurrence10aSkin10aSkin Diseases, Bacterial1 aBrandão MLFB1 aLima CMO1 aPiñeiro-Maceira J1 aMiranda A1 aOliveira LM W00aEarly diagnosis of relapse in borderline leprosy: two case reports.  uhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652011000600008&lng=en&nrm=iso&tlng=en  a341-30 v533 a<p>Two cases of relapse in borderline leprosy were reported. Despite the late-reversal, reaction-like feature, the suspicion of relapse in both was based on persistent and slow-developing skin lesions and an absence of acute neuritis or reaction during one year of follow-up. The authors have considered this possible occurrence in lepromatous borderline-treated patients after their immune cellular restoration and defend that not all Type 1 reactions would be an inflammatory answer to persistent Mycobacterium leprae, but that they could be. Therefore, a relapse diagnosis could be applied and it is more advisable, as one year of Multi-Drug Therapy (MDT) is less dangerous and more efficient for these cases than one year of corticosteroids.</p>  a1678-9946